Effect of blockade of the EGF system on wound healing in patients vaccinated with CIMAvax® EGF
Authors:
- Aymara Fernández LorenteALAymara Fernández Lorente
- Soraida Acosta BrooksSBSoraida Acosta Brooks
- Elia Neninger VinagerasEVElia Neninger Vinageras
- María C Barroso AlvarezMAMaría C Barroso Alvarez
- Barbara Wilkinson BritoBBBarbara Wilkinson Brito
- Mayelin Troche ConcepciónMCMayelin Troche Concepción
- Liana B Martínez PérezLPLiana B Martínez Pérez
- Carmen E Viada GonzálezCGCarmen E Viada González
- Tatiana Crespo DiazTDTatiana Crespo Diaz
- Angel R Casacó ParadaAPAngel R Casacó Parada
Open Access
- 1 January 2013
- journal article
- case report
- Published by Springer Nature in World Journal of Surgical Oncology
- Vol. 11 (1) , 275
Abstract
The epidermal growth factor receptor (EGFR) signaling system is frequently unbalanced in human malignancies due to increased ligand production, receptor overexpression, receptor mutations, and/or cross-talk with other receptor systems. For this reason, the EGFR is an attractive target for anticancer therapy. The epidermal growth factor also plays an important role in regulating multiple facets of cutaneous wound healing, including inflammation, wound contraction, proliferation, migration, and angiogenesis. In the Center of Molecular Immunology, a cancer vaccine is produced (CIMAvax® EGF) that blocks the binding of EGF to its receptor. This blockade causes a significant inverse association between the anti-EGF antibody titers and EGF concentration. Around 1,500 patients with non-small cell lung cancer have been treated, showing that this vaccine is safe, immunogenic, increases survival and improves quality of life. Taking into account the therapeutic benefits of CIMAvax® EGF vaccination and the role of EGF-EGFR system in the wound healing process, we decided to conduct a retrospective research with the aim of determining the effect to the CIMAvax® EGF vaccine on the wound healing process in patients undergoing surgical treatment.Keywords
This publication has 26 references indexed in Scilit:
- Safety of bevacizumab in metastatic breast cancer patients undergoing surgeryEuropean Journal of Cancer, 2012
- EGFR Enhances Early Healing After Cutaneous Incisional WoundingJournal of Investigative Dermatology, 2004
- Epidermal growth factor-based cancer vaccine for non-small-cell lung cancer therapyAnnals of Oncology, 2003
- Overexpression of epidermal growth factor and hepatocyte growth factor receptors in a proportion of gastrinomas correlates with aggressive growth and lower curability.2002
- Activation of epidermal growth factor receptor during corneal epithelial migration.2000
- A novel cancer vaccine composed of human-recombinant epidermal growth factor linked to a carrier protein: Report of a pilot clinical trialAnnals of Oncology, 1998
- The Role of Growth Factors in Wound HealingThe Journal of Trauma: Injury, Infection, and Critical Care, 1996
- Growth factors and wound healing: Biochemical properties of growth factors and their receptorsThe American Journal of Surgery, 1993
- Structural alterations of the epidermal growth factor receptor gene in human gliomas.Proceedings of the National Academy of Sciences, 1992
- Epithelial Wound Healing Enhanced by Transforming Growth Factor-α and Vaccinia Growth FactorScience, 1987